Aptamer-Based Immunotheranostic Strategies

Melián, María Fernanda García; Moreno, María; Cerecetto, Hugo; Calzada, Victoria

doi:10.1089/cbr.2022.0064

Cited by 5 publications

(6 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to widen the therapeutic scope, recently an alternate approach involving multiple markers was identified through Boolean logic. This led to the development of several logic-based methods to identify multiple biomarkers . Further, by coupling the above logic-based methods with photosensitizers or radioisotope labels on aptamers, such logic computing reactions could be extended precisely for photodynamic therapy.…”

Section: Immunotherapymentioning

confidence: 99%

See 1 more Smart Citation

Recent Advancements of Aptamers in Cancer Therapy

Venkatesan,

Chanda,

Balamurali

2023

ACS Omega

View full text Add to dashboard Cite

Aptamers are chemical antibodies possessing the capability of overcoming the limitations posed by conventional antibodies, particularly for diagnostic, therapeutic, and theranostic applications in cancer. The ease of chemical modifications or functionalization, including conjugations with nucleic acids, drug molecules, and nanoparticles, has made these aptamers to gain priorities in research. In this Mini-review, various reports on therapeutics with aptamer-functionalized nanomaterials for controlled or multistep drug release, targeted delivery, stimuliresponsive drug release, etc. are discussed. In the case of nucleicacid-conjugated aptamers, DNA nanotrains and DNA beacons are discussed in terms of the possibility of multidrug loading for chemotherapy and gene therapy. Developments with electrochemical aptasensors and signal-enhanced immune aptasensors are also discussed. Further, the future scope of aptamer technology in cancer theranostics and the prevailing limitations are discussed.

show abstract

Section: Immunotherapymentioning

confidence: 99%

“…This led to the development of several logic-based methods to identify multiple biomarkers. 30 Further, by coupling the above logic-based methods with photosensitizers or radioisotope labels on aptamers, such logic computing reactions could be extended precisely for photodynamic therapy.…”

Section: Immunotherapymentioning

confidence: 99%

Recent Advancements of Aptamers in Cancer Therapy

Venkatesan,

Chanda,

Balamurali

2023

ACS Omega

View full text Add to dashboard Cite

show abstract

“…There has been gradually increasing awareness of the potential role of aptamers in modulating the neuroinflammatory response in NDDs [206][207][208]. Uncontrolled and persistent neuroinflammation constitutes a pivotal factor in the progression of NDDs.…”

Section: Therapeutic Aptamers Targeting Neuroinflammationmentioning

confidence: 99%

“…Cellular heterogeneity poses significant challenges due to the complex and dynamic nature of immune responses [207,256]. The use of aptamers targeting biomarkers on immune cells such as clusters of differentiation (CD) and receptors may appear to offer increased specificity and targeted effects.…”

Section: Complex Challengesmentioning

confidence: 99%

Exploring the Potential of Aptamers in Targeting Neuroinflammation and Neurodegenerative Disorders: Opportunities and Challenges

Kong

et al. 2023

IJMS

View full text Add to dashboard Cite

Neuroinflammation is the precursor for several neurodegenerative diseases (NDDs), such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS). Targeting neuroinflammation has emerged as a promising strategy to address a wide range of CNS pathologies. These NDDs still present significant challenges in terms of limited and ineffective diagnosis and treatment options, driving the need to explore innovative and novel therapeutic alternatives. Aptamers are single-stranded nucleic acids that offer the potential for addressing these challenges through diagnostic and therapeutic applications. In this review, we summarize diagnostic and therapeutic aptamers for inflammatory biomolecules, as well as the inflammatory cells in NDDs. We also discussed the potential of short nucleotides for Aptamer-Based Targeted Brain Delivery through their unique features and modifications, as well as their ability to penetrate the blood-brain barrier. Moreover, the unprecedented opportunities and substantial challenges of using aptamers as therapeutic agents, such as drug efficacy, safety considerations, and pharmacokinetics, are also discussed. Taken together, this review assesses the potential of aptamers as a pioneering approach for target delivery to the CNS and the treatment of neuroinflammation and NDDs.

show abstract

“…Recent reports have also highlighted aptamer applications for imaging and diagnosis, suggesting their potential as valuable tools for diagnosing and imaging various cancers ( Soontornworajit and Wang, 2011 ; Zhang et al, 2019 ; Ning et al, 2020 ; Zhong et al, 2020 ; Cong et al, 2023 ). Despite the advantages aptamers offer over antibodies, numerous challenges must be addressed before aptamer-based therapeutics or imaging tools for various cancer types can be developed ( Ni et al, 2017 ; Mo et al, 2022 ; Wang et al, 2022 ; García Melián et al, 2023 ).…”

Section: Introductionmentioning

confidence: 99%

Theranostic potential of a novel aptamer specifically targeting HER2 in breast cancer cells

KÜÇÜKCANKURT,

UÇAK,

ALTIOK

2024

Turkish Journal of Biology

View full text Add to dashboard Cite

Background/aim The overexpression of HER2 is correlated with poorer outcomes and therapeutic resistance in breast cancer patients. While HER2-targeted therapies have shown improvement, prognosis remains poor for HER2-positive breast cancer patients, and these treatments have limitations. Therefore, it is crucial to explore effective molecular strategies for early detection and treatment of HER2-positive breast cancers. Materials and methods In this study, we employed the cell-SELEX method to generate a selective aptamer capable of recognizing HER2 in its native conformation within breast cancer cells, for theranostic applications. Utilizing an adherent cell-SELEX approach, we developed and explored a DNA aptamer, named HMAP7, which can specifically target HER2 in the MDA-MB-453 and SK-BR-3 human breast cancer cell lines. After sequencing, the binding affinities of 10 candidate aptamers to HER2 receptors were evaluated by measuring fluorescence intensities within intact cells using near-infrared optical imaging. The dissociation constant of HMAP7 was determined to be in the nanomolar range in both cell lines. Results The cell-SELEX-derived aptamer sequence, HMAP7 (41-mer), exhibited the highest binding affinity and specificity for HER2. HMAP7 was rapidly internalized into breast cancer cells overexpressing HER2 but showed no uptake in the HER2 receptor-deficient breast cancer cell line MDA-MB-231. Moreover, HMAP7 demonstrated remarkable selectivity for HER2, rendering it suitable for use in complex biological systems. Conclusions Our findings suggest that the novel DNA aptamer HMAP7 holds promise for both therapeutic and diagnostic applications, enabling selective delivery of therapeutic agents or imaging of HER2-positive breast tumors.

show abstract

Aptamer-Based Immunotheranostic Strategies

Cited by 5 publications

References 110 publications

Recent Advancements of Aptamers in Cancer Therapy

Recent Advancements of Aptamers in Cancer Therapy

Exploring the Potential of Aptamers in Targeting Neuroinflammation and Neurodegenerative Disorders: Opportunities and Challenges

Theranostic potential of a novel aptamer specifically targeting HER2 in breast cancer cells

Contact Info

Product

Resources

About